Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use
Top Cited Papers
- 1 March 2000
- journal article
- Published by Wolters Kluwer Health in PAIN®
- Vol. 85 (1) , 169-182
- https://doi.org/10.1016/s0304-3959(99)00267-5
Abstract
Randomised controlled trials (RCTs) alone are unlikely to provide reliable estimates of the incidence of rare events because of their limited size. Cohort, case control, and other observational studies have large numbers but are vulnerable to various kinds of bias. Wanting to estimate the risk of death from bleeding or perforated gastroduodenal ulcers with chronic usage of non-steroidal anti-inflammatory drugs (NSAIDs) with greater precision, we developed a model to quantify the frequency of rare adverse events which follow a biological progression. The model combined data from both RCTs and observational studies. We searched systematically for any report of chronic (>/=2 months) use of NSAIDs which gave information on gastroduodenal ulcer, bleed or perforation, death due to these complications, or progression from one level of harm to the next. Fifteen RCTs (19364 patients exposed to NSAIDs for 2-60 months), three cohort studies (215076 patients redeeming a NSAID prescription over a 3-12 month period), six case-control studies (2957 cases) and 20 case series (7406), and case reports (4447) were analysed. In RCTs the incidence of bleeding or perforation in 6822 patients exposed to NSAIDs was 0.69%; two deaths occurred. Of 11040 patients with bleeding or perforation with or without NSAID exposure across all reports, 6-16% (average 12%) died; the risk was lowest in RCTs and highest in case reports. Death from bleeding or perforation in all controls not exposed to NSAIDs occurred in 18 out of 849489 (0.002%). From these numbers we calculated the number-needed-to-treat for one patient to die due to gastroduodenal complications with chronic (>/=2 months) NSAIDs as 1/((0.69x¿6-16%, average 12%¿)-0.002%))=909-2500 (average 1220). On average 1 in 1200 patients taking NSAIDs for at least 2 months will die from gastroduodenal complications who would not have died had they not taken NSAIDs. This extrapolates to about 2000 deaths each year in the UK.Keywords
This publication has 63 references indexed in Scilit:
- Emergency admissions for upper gastrointestinal disease and their relation to NSAID useAlimentary Pharmacology & Therapeutics, 1997
- Why we need observational studies to evaluate the effectiveness of health careBMJ, 1996
- Misoprostol coadministered with diclofenac for prevention of gastroduodenal ulcersDigestive Diseases and Sciences, 1995
- From Emergency Room to MorgueAmerican Journal of Forensic Medicine & Pathology, 1994
- Risk and Cost of Gastrointestinal Side Effects Associated With Nonsteroidal Anti-inflammatory DrugsArchives of internal medicine (1960), 1989
- Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration.Gut, 1987
- Nonsteroidal Anti-inflammatory Drugs and Gastrointestinal BleedingArchives of internal medicine (1960), 1986
- Non-steroidal anti-inflammatory drugs and serious gastrointestinal adverse reactions--2.BMJ, 1986
- CSM Update: Non-steroidal anti-inflammatory drugs and serious gastrointestinal adverse reactions--1BMJ, 1986
- Mortality of perforated duodenal ulcer treated by simple sutureBritish Journal of Surgery, 1971